



NEWS RELEASE

Contact: Bill Wells
404-281-7490

AerovectRx Granted Notice of Allowance for Key Patent Claims

ATLANTA (April 10, 2007) – AerovectRx Corporation, developer of new unit dose aerosol drug delivery technology, today announced that the U.S. Patent and Trademark Office has indicated its intent to grant a patent for the first key claims of the Company’s platform technology.

“This is the first of several patents we expect to be issued covering our electronic, vibrating mesh aerosol drug delivery technology with a disposable unit-dosage drug cartridge featuring a disposable mesh,” said Matthew H.J. Kim, J.D., founder and CEO of AerovectRx. “We believe that this first Notice of Allowance and our 510(k) clearance from the FDA are further validations of the strength of our intellectual property and our unique approach to aerosol drug delivery. These claims also extend the application of our technology from the hospital and home care markets where nebulizers are commonly used to specialized applications where the system can be coupled with a high-end value drug.”

The AerovectRx nebulizer technology, licensed from the U.S. Centers for Disease Control and Prevention (CDC), delivers novel therapies and vaccines in an easy to breathe mist. The technology employs a disposable vibrating mesh that can be integrated as part of either a user-filled or pre-filled medication cartridge, which allows for improved dosage control and efficient aerosolization while minimizing risks of re-infection which can be especially critical in settings where symptoms of conditions such as cystic fibrosis and pneumonia are treated with antibiotics.

Pulmonary, or inhaled, drug delivery offers a significant improvement in the administration of certain drugs, and in some instances, provides new therapeutic options for the treatment of disease. Inhaled drugs are rapidly delivered to the bloodstream for treatment of systemic diseases, or to the lung for treatment of local, respiratory diseases. The annual market for inhaled drug delivery is estimated at \$12 billion.

About AerovectRx --

AerovectRx Corporation is an aerosol therapeutic company providing unit-dose customizable and scalable delivery solutions using the air we breathe as the gateway for better living. Products under development by AerovectRx are designed to deliver a wide variety of therapies for respiratory and non-

###More###

AerovectRx/Notice of Allowance

April 10, 2007

Page 2

respiratory systemic conditions. Potential targeted therapeutic candidates for the AerovectRx technology include treatments for asthma, cystic fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), diabetes, pain management, and for delivery of vaccines and anti-viral drugs. For more information, visit www.aerovectrx.com.

###END###